3Senn S.Individual response to treatment:is it a valid assumption?[J].BMJ,2004,329(7 472):966.
4Dervieux T,Meshkin B.Pharmacogenetic testing:proofs of principle and pharmacoeconomic implications[J].Mutat Res,2005,573(1～ 2):180.
5Camp ER,Summy J,Bauer TW,et al.Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor[J].Cli Cancer Res,2005,11 (1):397.
7Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J].Science,2004,304(5 676):1 497.
8Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786.
9Laupeze B,Amiot L,Drenou B,et al.High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival[J].Br J Haematol,2002,116(4):834.
10Van der Holt B,Lowenberg B,Burnett AK,et al.The value of the MDR1 reversal agent PSC833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia(AML),in relation to MDR1 status at diagnosis[J].Blood,2005,106(8):2 646.
6Krajinovic M, Robaey P, Chiasson S, et al.Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL[J]. Pharmacogenomics, 2005, 6(3):293.
7Laverdiere C, Chiasson S, Costea I, et al. Polymorphism GSOA in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia[J]. Blood, 2002, 100 (10) :3 832.
8Kxajinovic M, Costea I, Primeau M, et al. Combining several polymorphisms of thymidylate synthase gene for pharmacogcnetic analysis[J].Pharmacogenomics J, 2005, 5(6):374.
9Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia[J]. J Clin Oncol, 2004, 22 (19) : 3 930.
10Fleury I, Primeau M, Doreau A, et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia[J]. Am J Pharmacogenomics, 2004, 4(5) : 331.
